Reviewed and edited 17th August 2026
The short answer
Neuroendocrine cancer is difficult to detect because many grow slowly, behave unpredictably, and often hide behind common, misleading symptoms. Even with modern imaging and pathology, many tumours remain invisible until they metastasise. That’s why NETs are often described as “a needle in a haystack.”
Why Neuroendocrine Cancer Is So Hard to Find
Neuroendocrine neoplasms (NENs) are uncommon, heterogeneous, and frequently misdiagnosed. They mimic everyday conditions such as IBS, asthma, menopause, anxiety, gallbladder disease, and acid reflux. This symptom overlap leads to long diagnostic delays — often 5–7 years from first symptoms to confirmed diagnosis.
Three factors drive this challenge:
- Slow growth: many NETs progress quietly for years.
- Functional vs non‑functional behaviour: hormone‑producing tumours behave differently from silent ones.
- Small, hidden primaries: especially in the small intestine, pancreas, and lung.
These characteristics make NETs fundamentally different from most solid tumours.
Cancer of Unknown Primary (CUP): When the Haystack Is Even Bigger
CUP occurs when metastatic cancer is found but the primary tumour cannot be identified. NETs are one of the most common cancers associated with CUP because:
- Small intestinal primaries can be microscopic.
- Pancreatic NETs may remain occult even with high‑resolution imaging.
- Lung NETs can be missed on standard CT.
- Liver metastases often appear before the primary is visible.
Older patients are disproportionately affected — over 60% of CUP cases occur in people aged 75+ — but NET‑related CUP can occur at any age.
For NET patients, CUP is not a failure of medicine; it’s a reflection of how stealthy these tumours can be.
Imaging: Powerful, But Not Perfect
Modern imaging has transformed NET diagnosis, but limitations remain.
CT and MRI
Excellent for liver metastases, lymph nodes, and larger primaries — but small bowel NETs often evade detection.
Somatostatin receptor imaging (SSTR PET)
Ga‑68 DOTATATE and Cu‑64 DOTATATE PET/CT scans are now standard (but some countries lack the quantity needed). They detect many primaries, but not all:
- Very small lesions may not express enough receptor.
- High‑grade NECs often have low SSTR expression.
- Fibrotic mesenteric masses can obscure the true origin.
Endoscopy and capsule endoscopy
Useful for GI NETs, but still not guaranteed to find the primary.
Imaging is powerful — but NETs are often more powerful at hiding.
Biopsy and Immunohistochemistry (IHC): Clues, Not Certainty
Biopsy remains essential, but even IHC has limits.
Markers such as chromogranin A, synaptophysin, INSM1, Ki‑67, and site‑specific stains can suggest the tumour’s origin — but they cannot always confirm it 100% with certainty.
Most NET patients do eventually learn their primary site, but a small minority remain challenging. This is especially true for:
- Small intestinal NETs
- Pancreatic NETs
- Lung NETs
- High‑grade NECs
In these cases, treatment focuses on biology and behaviour rather than location.
Multiple Primaries: When There’s More Than One Needle
Some patients have more than one NET primary, especially in the small intestine. Surgeons often use the “Mark 1 eyeball” technique — manually inspecting the bowel during surgery — because imaging may miss additional tumours.
This is not rare. It’s a recognised feature of small bowel NET biology.
Metastasis Patterns: Where NETs Hide
NETs can spread to common and uncommon locations:
- Liver — the most frequent site
- Lymph nodes
- Bone
- Peritoneum
- Lung
- Brain (very rare)
- Breast (rare)
- Heart (extremely rare)
Unusual metastases do not necessarily indicate aggressive disease; they often reflect long‑standing, slow‑growing biology.
NEC vs NET: Why Grade Matters
The 2026 WHO classification emphasises the importance of tumour grade:
- NET G1–G2: well‑differentiated, slow‑growing
- NET G3: well‑differentiated but faster – eqeal to or less than 55% can often benefit from G2 treatments
- NEC: poorly differentiated, high‑grade, often Ki‑67 >55%
NEC behaves very differently from NET. It spreads faster, responds differently to treatment, and is more likely to present as CUP.
Understanding grade is essential for prognosis and therapy.
MiNEN: When Two Cancers Co‑Exist
Mixed neuroendocrine–non‑neuroendocrine neoplasms (MiNENs) contain both NET/NEC and adenocarcinoma components. They are rare but important because:
- They can complicate diagnosis.
- Treatment may need to target both components.
- The non‑neuroendocrine part may drive behaviour.
MiNENs are another reason why NETs can be difficult to classify.
How We Improve Detection
Several tools help clinicians find the “needle” more reliably:
- High‑resolution SSTR PET
- Multiphasic liver MRI/CT
- Endoscopic ultrasound (EUS)
- Advanced pathology panels
- Genomic profiling
- Emerging molecular diagnostics
- More experienced NET centres
Specialist Knowledge – certain things are known about the behaviour of NENs
Early referral to a specialist centre remains one of the most important steps. Education and awareness is absolutely key – thus why I created the website RonnyAllan.NET
Summary
Neuroendocrine cancer is difficult to detect because it very often grows slowly, hides in complex anatomy, and often produces misleading symptoms. Even with modern imaging and pathology, many primaries remain invisible. But with improved scans, better pathology, and increasing awareness, detection is steadily improving. NETs may be a needle in a haystack — but the haystack is gradually getting smaller.
Check out my WEGO Health Awards
Check out my Glossary of Terms – click here
Please Share this post for Neuroendocrine Cancer awareness and to help another patient
Please Share this post for Neuroendocrine Cancer awareness and to help another patient
Discover more from Ronny Allan - Living with Neuroendocrine Cancer
Subscribe to get the latest posts sent to your email.
Very useful information, Ronny. Thank you!
This is a brilliant overview, Ronny. I’m between three-monthly CT scans as part of a surveillance regime (PNET primary, liver metastases, both ‘disappeared’ – for now) and your blog keeps me abreast of developments and progress in diagnostic tools and treatments.
Thank you thank you